Kala Bio KALA
NASDAQ KALA
$0.82 -0.02 (-2.39%)
As of: Aug 21, 2026 · 3:58 PM EDT

Kala Bio (KALA) Non-Current Deferred Tax Liability (2017 - 2024)

Kala Bio (KALA) posted Non-Current Deferred Tax Liability of $499000.0 for Q4 2024, down 21.79% sequentially from $638000.0 in Q4 2023, and down 21.79% YoY from $638000.0 in Q1 2024.

Kala Bio (KALA) Non-Current Deferred Tax Liability (2017 - 2024) Analysis & Trends

Kala Bio has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $499000.0 in Q4 2024.

  • Quarterly Non-Current Deferred Tax Liability fell 21.79% year-over-year to $499000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $499000.0 (down 21.79% YoY) and the FY2024 annual result came in at $499000.0, down 21.79% from the prior year.
  • Non-Current Deferred Tax Liability eased to $499000.0 in Q4 2024 per KALA's latest filing, from $638000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $7.8 million in Q4 2020 and troughed at $4000.0 in Q4 2022.
  • A 5-year average of $1.9 million and a median of $499000.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability plunged 98.79% in 2022, then surged 15850.0% in 2023.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $7.8 million in 2020, then tumbled by 95.76% to $331000.0 in 2021, then slumped by 98.79% to $4000.0 in 2022, then soared by 15850.0% to $638000.0 in 2023, then decreased by 21.79% to $499000.0 in 2024.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $499000.0, $638000.0, and $4000.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Kala Bio 9.89 Mn 9.89 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 499,000.00
Dec 31, 2024 499,000.00
Dec 31, 2023 638,000.00
Dec 31, 2023 638,000.00
Dec 31, 2022 4,000.00
Dec 31, 2022 4,000.00
Dec 31, 2021 331,000.00
Dec 31, 2021 331,000.00
Dec 31, 2020 7.81 Mn
Dec 31, 2020 7.81 Mn
Dec 31, 2019 9.18 Mn
Dec 31, 2019 9.18 Mn
Dec 31, 2018 8.22 Mn
Dec 31, 2018 8.22 Mn
Dec 31, 2017 9,000.00
Dec 31, 2017 9,000.00